Benzinga · Oct 2, 2026
TD Cowen Maintains Buy on CeriBell, Raises Price Target to $33
TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $29 to $33.
CB
NASDAQ · CBLL
CeriBell, Inc. Common Stock
Healthcare · Medical - Devices
$23.48
Down-$0.86 (-3.53%)
Updated Oct 8, 2026, 8:39 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 757.49M
- P/E ratio
- -14.33
- Dividend yield
- 0.00%
- 52-week range
- $10.85 – $25.63
- Volume
- 305.4K
- Avg. volume
- 348.13K
Price performance · CBLL
CBLL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
CBLL closed at $23.48 after 21 trading sessions, down 3.81% for the selected period.
- Last close
- $23.48
- Period change
- -3.81%
- Period low
- $23.43
- Period high
- $25.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $24.20 | $24.55 | $23.43 | $23.48 | 305.4K |
| Oct 6, 2026 | $24.95 | $25.1031 | $24.22 | $24.34 | 241.74K |
| Oct 5, 2026 | $23.67 | $25.045 | $23.67 | $24.86 | 239.51K |
| Oct 2, 2026 | $24.18 | $24.19 | $23.315 | $23.69 | 307.03K |
| Oct 1, 2026 | $24.38 | $24.54 | $23.50 | $23.61 | 316.7K |
| Sep 30, 2026 | $25.00 | $25.25 | $24.36 | $24.39 | 336.29K |
| Sep 29, 2026 | $24.51 | $24.90 | $24.03 | $24.86 | 300.86K |
| Sep 28, 2026 | $23.61 | $24.59 | $23.52 | $24.51 | 217.93K |
| Sep 25, 2026 | $23.87 | $23.88 | $23.3773 | $23.69 | 270.58K |
| Sep 24, 2026 | $23.62 | $23.90 | $23.19 | $23.82 | 215.08K |
| Sep 23, 2026 | $24.08 | $24.22 | $23.3306 | $23.62 | 353.81K |
| Sep 22, 2026 | $24.47 | $24.68 | $24.11 | $24.25 | 349.79K |
| Sep 21, 2026 | $24.51 | $24.66 | $24.00 | $24.25 | 309.47K |
| Sep 18, 2026 | $24.89 | $25.31 | $24.33 | $24.37 | 931.89K |
| Sep 17, 2026 | $24.97 | $25.25 | $24.485 | $25.00 | 734.95K |
| Sep 16, 2026 | $25.62 | $25.6269 | $24.34 | $24.50 | 461.68K |
| Sep 15, 2026 | $24.42 | $25.12 | $23.90 | $25.04 | 323.52K |
| Sep 14, 2026 | $23.65 | $24.61 | $23.645 | $24.33 | 280.71K |
| Sep 11, 2026 | $23.65 | $23.65 | $23.04 | $23.63 | 255.08K |
| Sep 10, 2026 | $24.13 | $24.29 | $23.11 | $23.43 | 220.13K |
| Sep 9, 2026 | $24.00 | $24.66 | $23.65 | $24.41 | 255.27K |
Latest CBLL news
The latest Smart Investors Daily articles mentioning CBLL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CBLL research
Overview
Company profile and research snapshot.
Company profile
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $30.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 2, 2026 | TD Cowen | Buy | — |
| Sep 11, 2026 | BTIG | Buy | — |
| Aug 18, 2026 | BTIG | Buy | — |
| Aug 11, 2026 | BTIG | Buy | — |
| Aug 11, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 1, 2026
CeriBell: FDA Clearances And Delirium Expansion Could Create A New Growth Driver
CeriBell is poised for significant growth as it expands its seizure detection platform into new neurological applications. Read why CBLL stock is a Hold.
Yahoo · Sep 30, 2026
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indicationsSUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared new software for the Cer
Benzinga · Sep 11, 2026
BTIG Reiterates Buy on CeriBell, Maintains $30 Price Target
BTIG analyst Marie Thibault reiterates CeriBell (NASDAQ:CBLL) with a Buy and maintains $30 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
